Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name MEDI5752
Synonyms
Therapy Description

MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MEDI5752 MEDI-5752|MEDI 5752|volrustomig CTLA4 Antibody 29 Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03530397 Phase I Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Active, not recruiting USA | NLD | ITA | FRA | ESP | AUS 3
NCT06079671 Phase III MEDI5752 Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) Recruiting USA | ITA | ESP | CAN 13
NCT06129864 Phase III MEDI5752 A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 10
NCT05888857 Phase II MEDI5752 A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (TAYLOR) Not yet recruiting FRA 0
NCT05775159 Phase II Lenvatinib + MEDI5752 Bevacizumab + MEDI5752 MEDI5752 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer Recruiting USA | ITA | GBR | ESP 5
NCT05821231 Phase I MEDI5752 Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT) Recruiting FRA 0


Additional content available in CKB BOOST